Scientific Publications on Global Measles

Updated November 16, 2023

These scientific publications are authored or co-authored by CDC scientists and/or funded by CDC’s Global Immunization Division, Center for Global Health.


Progress Toward Regional Measles Elimination — Worldwide, 2000–2022.
Minta AA, Ferrari M, Antoni S, et al. MMWR Morb Mortal Wkly Rep 2023;72:1262–1268. doi: 10.15585/mmwr.mm7246a3.

Progress Toward Measles and Rubella Elimination – Indonesia, 2013-2022.
Chacko S, Kamal M, Endang, BH et al. MMWR Morb Mortal Wkly Rep. 2023:72:1134-1139. doi: 10.15585/mmwr.mm7242a2.

Lessons learnt from the applying the Centers for Disease Control and Prevention (CDC) evaluation framework to the measles incident management system response, USA, 2020–2021.
Jacenko A, Bough S, Grant G, et al. BMJ Glob Health. 2023;8(3):e011861.

Nationwide measles and rubella outbreaks in South Sudan, 2019.
Peck ME, Maleghemi S, Kayembe L, et al. Open Forum Infect Dis. 2023;10(2):ofad032.

Mapping the distribution of zero-dose children to assess the performance of vaccine delivery strategies and their relationships with measles incidence in Nigeria.
Utazi CE, Aheto JMK, Wigley A, et al. Vaccine. 2023;41(1):170-181. doi: 10.1016/j.vaccine.2022.11.026.


Measles susceptibility in maternal-infant dyads-Bamako, Mali.
Dixon MG, Tapia MG, Wannemuehler K, et al. Vaccine. 2022;S0264-410X(22)00027-5. doi: 10.1016/j.vaccine.2022.01.012.

Accelerating measles elimination in the Western Pacific Region during the calm between the storms.
Durheim D, Baker M, Capeding M, et al. Lancet Reg Health West Pac. 2022;23:100495. doi: 10.1016/j.lanwpc.2022.100495.

Innovations in vaccine delivery: Increasing access, coverage, and equity and lessons learnt from measles and rubella elimination.
Goodson JL, Rota PA. Drug Deliv Transl Res. 2022;12(5):959-967. doi: 10.1007/s13346-022-01130-9.

Progress toward measles elimination — South-East Asia Region, 2003–2020.
Khanal S, Kassem A, Bahl S, et al. MMWR Morb Mortal Wkly Rep. 2022;71(33):1042–1046. doi: 10.15585/mmwr.mm7133a2.

Use of a rapid digital microfluidics-powered immunoassay for assessing measles and rubella infection and immunity in outbreak settings in the Democratic Republic of the Congo.
Knipes AK, Summers A, Sklavounos AA, et al. PLoS One. 2022;17(12):e0278749. doi: 10.1371/jounral.pone.0278749.

Progress toward regional measles elimination — Worldwide, 2000 – 2021.
Minta AA, Ferrari M, Antoni S, et al. MMWR Morb Mortal Wkly Rep. 2022;71:1489-1495. doi: 10.15585/mmwr.mm7147a1.

Progress toward measles and rubella elimination — India, 2005–2021.
Murugan R, VanderEnde K, Dhawan V, et al. MMWR Morb Mortal Wkly Rep. 2022;71(50):1569–1575. doi: 10.15585/mmwr.mm7150a1.

Feasibility of measles and rubella vaccination programmes for disease elimination: A modelling study.
Winter AK, Lambert B, Klein D, et al. Lancet Glob Health. 2022;10(10):E1412-E1422. doi: 10.1016/S2214-109X(22)00335-7.


Development of a measles and rubella multiplex bead serological assay for assessing population immunity.
Coughlin MM, Matson Z, Sowers SB, et al. J Clin Microbiol. 2021;59(6):e02716-20. doi: 10.1128/JCM.02716-20.

Risk factors for measles deaths among children during a nationwide measles outbreak - Romania, 2016-2018.
Donadel M, Stanescu A, Pistol A, et al. BMC Infect Dis. 2021;(1):279. doi: 10.1186/s12879-021-05966-3.

Progress toward measles elimination — Worldwide, 2000-2020.
Dixon MG, Ferrari M, Antoni S, et al. MMWR Morb Mortal Wkly Rep. 2021;70(45):1563-1569. doi: 10.15585/mmwr.mm7045a1.

Measles in the 21st century: Progress toward achieving and sustaining elimination.
Gastañaduy PA, Goodson JL, Panagiotakopoulos L, Rota PA, Orenstein WA, Patel M. J Infect Dis. 2021;224(Supplement_4):S420-S428. doi: 10.1093/infdis/jiaa793.

Impact of COVID-19-related disruptions to measles, meningococcal A, and yellow fever vaccination in 10 countries.
Gaythorpe KA, Abbas K, Huber J, et al. Elife. 2021;10:e67023. doi: 10.7554/eLife.67023.

Feasibility assessment of measles and rubella eradication.
Moss WJ, Shendale S, Lindstrand A, et al. Vaccine. 2021;39(27):3544-3559. doi: 10.1016/j.vaccine.2021.04.027.

The changing global epidemiology of measles, 2013-2018.
Patel MK, Antoni S, Nedelec Y, et al. J Infect Dis. 2020;222(7):1117-1128. doi: 10.1093/infdis/jiaa044.


Rapid diagnostic tests to address challenges for global measles surveillance.
Brown DW, Warrener L, Scobie HM, et al. Curr Opin Virol. 2020;41:77–84. doi: 10.1016/j.coviro.2020.05.007.

Community-based surveillance in Côte d'Ivoire.
Clara A, Ndiaye SM, Joseph B, et al. Health Secur. 2020;18(S1):S23-S33. doi: 10.1089/hs.2019.0062.

What it will take to achieve a world without measles.
Cochi SL, Schluter WW. J Infect Dis. 2020;222(7):1073–1075. doi: 10.1093/infdis/jiaa045.

Vaccination coverage survey and seroprevalence among forcibly displaced Rohingya children, Cox's Bazar, Bangladesh, 2018: A cross-sectional study.
Feldstein LR, Bennett SD, Estivariz CF, et al. PLoS Med. 2020;17(3):e1003071. doi: 10.1371/journal.pmed.1003071.

Access, demand, and utilization of childhood immunization services: A cross-sectional household survey in Western Area Urban district, Sierra Leone, 2019.
Feldstein LR, Sutton R, Jalloh MF, et al. J Glob Health. 2020;10(1):010420. doi: 10.7189/jogh.10.010420.

Recent setbacks in measles elimination: The importance of investing in innovations for immunizations.
Goodson JL. Pan Afr Med J. 2020;35(Suppl 1):15. doi: 10.11604/pamj.supp.2020.35.1.21740.

Progress toward measles elimination — Eastern Mediterranean Region, 2013–2019.
Goodson J, Teleb N, Ashmony H, et al. MMWR Morb Mortal Wkly Rep. 2020;69(15):439–445. doi: 10.15585/mmwr.mm6915a2.

Assessment of VaxTrac electronic immunization registry in an urban district in Sierra Leone: implications for data quality, defaulter tracking, and policy.
Jalloh MF, Namageyo-Funa A, Gleason B, et al. Vaccine. 2020;38(39):6103–6111. doi: 10.1016/j.vaccine.2020.07.031.

High risk of subacute sclerosing panencephalitis following measles outbreaks in Georgia.
Khetsuriani N, Sanadze K, Abuladze M, Tatishvili N. Clin Microbiol Infect. 2020;26(6):737–742. doi: 10.1016/j.cmi.2019.10.035.

Challenges to achieving measles elimination, Georgia, 2013–2018.
Khetsuriani N, Sanadze K, Chlikadze R, et al. Emerg Infect Dis. 2020;26(11):2565–2577. doi: 10.3201/eid2611.200259.

Risk factors for measles virus infection and susceptibility in persons aged 15 years and older in China: A multi-site case-control study, 2012-2013.
Ma C, Hao L, Rodewald L, et al. Vaccine. 2020;38(16):3210–3217. doi: 10.1016/j.vaccine.2020.03.006.

The African Region early experience with structures for the verification of measles elimination — A review.
Masresha B, Luce R, Tanifum P, Lebo E, Dosseh A, Mihigo R. Pan Afr Med J. 2020;35(Suppl 1):1. doi: 10.11604/pamj.supp.2020.35.1.19061.

The impact of a prolonged Ebola outbreak on measles elimination activities in Guinea, Liberia, and Sierra Leone, 2014–2015.
Masresha BG, Luce R Jr, Weldegebriel G, Katsande R, Gasasira A, Mihigo R. Pan Afr Med J. 2020;35(Suppl 1):8. doi: 10.11604/pamj.supp.2020.35.1.19059.

Seroprevalence of measles, rubella, tetanus, and diphtheria antibodies among children in Haiti, 2017.
Minta AA, Andre-Alboth J, Childs L, et al. Am J Trop Med Hyg. 2020;103(4):1717­–1725. doi: 10.4269/ajtmh.20-0112.

Action needed now to prevent further increases in measles and measles deaths in the coming years.
Mulholland K, Kretsinger K, Wondwossen L, Crowcroft N. Lancet. 2020;396(10265):1782–1784. doi: 10.1016/S0140-6736(20)32394-1.

Measles and rubella IgG seroprevalence in persons 6 months–35 years of age, Mongolia, 2016.
Nogareda F, Gunregjav N, Sarankhuu A, et al. Vaccine. 2020;38(26):4200–4208. doi: 10.1016/j.vaccine.2020.04.024.

The changing global epidemiology of measles, 2013–2018.
Patel MK, Antoni S, Nedelec Y, et al. J Infect Dis. 2020;222(7):1117–1128. doi: 10.1093/infdis/jiaa044.

Progress toward regional measles elimination — Worldwide, 2000–2019.
Patel MK, Goodson JL, Alexander JP Jr., et al. MMWR Morb Mortal Wkly Rep. 2020;69:1700–1705. doi: 10.15585/mmwr.mm6945a6.

A microneedle patch for measles and rubella vaccination: A game changer for achieving elimination.
Prausnitz MR, Goodson JL, Rota PA, Orenstein WA. Curr Opin Virol. 2020;41:68–76. doi: 10.1016/j.coviro.2020.05.005.

Progress towards measles elimination in Eritrea: 2003–2018.
Yehdego T, Yhdego TK, Masresha B, et al. Pan Afr Med J. 2020;35(Suppl 1):7. doi: 10.11604/pamj.supp.2020.35.1.19126.


Spread of measles in Europe and implications for US travelers.
Angelo KM, Gastañaduy PA, Walker AT, et al. Pediatrics. 2019;144(1):e20190414. doi: 10.1542/peds.2019-0414.

Successes and challenges for preventing measles, mumps and rubella by vaccination.
Bankamp B, Hickman C, Icenogle JP, Rota PA. Curr Opin Virol. 2019;34:110-116. doi: 10.1016/j.coviro.2019.01.002.

Use of FTA cards to transport throat swabs and oral fluid samples for molecular detection and genotyping of measles and rubella viruses.
Bankamp B, Sein C, Pukuta Simbu E, et al. J Clin Microbiol. 2019;57(5). doi: 10.1128/JCM.00048-19.

Genetic characterization of measles and rubella viruses detected through global measles and rubella elimination surveillance, 2016­–2018.
Brown KE, Rota PA, Goodson JL, et al. MMWR Morb Mortal Wkly Rep. 2019;68(26):587–591. doi: 10.15585/mmwr.mm6826a3.

Combining serological and contact data to derive target immunity levels for achieving and maintaining measles elimination.
Funk S, Knapp JK, Lebo E, et al. BMC Med. 2019;17(1):180. doi: 10.1186/s12916-019-1413-7.

Accelerating measles and rubella elimination through research and innovation — Findings from the Measles & Rubella Initiative research prioritization process, 2016.
Grant GB, Masresha BG, Moss WJ, et al. Vaccine. 2019;37(38):5754-5761. doi: 10.1016/j.vaccine.2019.01.081.

Evaluating vaccination policies to accelerate measles elimination in China: A meta-population modelling study.
[published correction appears in Int J Epidemiol. 2019 Aug 1;48(4):1385].
Hao L, Glasser JW, Su Q, et al. Int J Epidemiol. 2019;48(4):1240-1251. doi: 10.1093/ije/dyz058.

The clinical impact and cost-effectiveness of measles-mumps-rubella vaccination to prevent measles importations among international travelers from the United States.
Hyle EP, Fields NF, Fiebelkorn AP, et al. Clin Infect Dis. 2019;69(2):306-315. doi: 10.1093/cid/ciy861.

Measles and rubella seroprevalence among adults in Georgia in 2015: Helping guide the elimination efforts.
Khetsuriani N, Chitadze N, Russell S, Ben Mamou M. Epidemiol Infect. 2019;147:e319. doi: 10.1017/S0950268819002048.

Research priorities for accelerating progress toward measles and rubella elimination identified by a cross-sectional web-based survey.
Kriss JL, Grant GB, Moss WJ, et al. Vaccine. 2019;37(38): 5745–5753. doi: 10.1016/j.vaccine.2019.02.058.

International importations of measles virus into the United States during the postelimination era, 2001–2016.
Lee AD, Clemmons NS, Patel M, Gastañaduy PA. J Infect Dis. 2019;219(10):1616-1623. doi: 10.1093/infdis/jiy701.

Economic value of vaccinating geographically hard-to-reach populations with measles vaccine: A modeling application in Kenya.
Lee BY, Brown ST, Haidari LA, et al. Vaccine. 2019;37(17): 2377–2386. doi: 10.1016/j.vaccine.2019.03.007.

Increase in infant measles deaths during a nationwide measles outbreak — Mongolia, 2015–2016.
Lee CT, Hagan JE, Jantsansengee B, et al. J Infect Dis. 2019;220(11):1771-1779. doi: 10.1093/infdis/jiz140.

Immunogenicity and safety of measles-rubella vaccine co-administered with attenuated Japanese encephalitis SA 14–14–2 vaccine in infants aged 8 months in China: a non-inferiority randomised controlled trial.
Li Y, Chu SY, Yue C, et al. Lancet. 2019;19(4):402–409. doi: 10.1016/S1473-3099(18)30650-9.

Progress toward measles elimination — China, January 2013–June 2019.
Ma C, Rodewald L, Hao L, et al. MMWR Morb Mortal Wkly Rep. 2019;68(48):1112–1116. doi: 10.15585/mmwr.mm6848a2.

Progress toward measles elimination — Pakistan, 2000–2018.
Mere MO, Goodson JL, Chandio AK, et al. MMWR Morb Mortal Wkly Rep. 2019;68(22):505–510. doi: 10.15585/mmwr.mm6822a4.

Immunogenicity, effectiveness, and safety of measles vaccination in infants younger than 9 months: A systematic review and meta-analysis.
Nic Lochlainn LM, de Gier B, van der Maas N, et al.  Lancet Infect Dis. 2019;19(11):1235–1245. doi: 10.1016/S1473-3099(19)30395-0.

Effect of measles vaccination in infants younger than 9 months on the immune response to subsequent measles vaccine doses: A systematic review and meta-analysis.
Nic Lochlainn LM, de Gier B, van der Maas N, et al. Lancet Infect Dis. 2019;19(11):1246–1254. doi: 10.1016/S1473-3099(19)30396-2.

Assessment of economic burden of concurrent measles and rubella outbreaks, Romania, 2011–2012.
Njau J, Janta D, Stanescu A, et al. Emerg Infect Dis. 2019;25(6):1101–1109. doi: 10.3201/eid2506.180339.

Progress toward regional measles elimination — Worldwide, 2000–2018.
Patel MK, Dumolard L, Nedelec Y, et al. MMWR Morb Mortal Wkly Rep. 2019;68(48):1105–1111. doi: 10.15585/mmwr.mm6848a1.

Classification of global measles cases in 2013–2017 as due to policy or vaccination failure: A retrospective review of global surveillance data.
Patel MK, Orenstein WA. Lancet Glob Health. 2019;7(3):e313–e320. doi: 10.1016/S2214-109X(18)30492-3.

Strebel PM, Orenstein WA. N Engl J Med. 2019;381(4):349–357. doi: 10.1056/NEJMcp1905181.

Measles and rubella immunity in the population of Bhutan, 2017.
Wangchuk S, Nogareda F, Tshering N, et al. Vaccine. 2019;37(43):6463–6469. doi: 10.1016/j.vaccine.2019.08.085.

Progress toward measles elimination — European Region, 2009–2018.
Zimmerman LA, Muscat M, Singh S, et al. MMWR Morb Mortal Wkly Rep. 2019;68(17):396–401. doi: 10.15585/mmwr.mm6817a4.

Selection From Previous Years

Progress toward regional measles elimination — Worldwide, 2000–2017.
Dabbagh A, Laws RL, Steulet C, et al. MMWR Morb Mortal Wkly Rep. 2018;67(47):1323–1329. doi: 10.15585/mmwr.mm6747a6.

Progress and challenges in measles and rubella elimination in the WHO European Region.
Datta SS, O'Connor PM, Jankovic D, et al. Vaccine. 2018;36(36):5408–5415. doi: 10.1016/j.vaccine.2017.06.042.

Measles outbreak response decision-making under uncertainty: A retrospective analysis.
Fonnesbeck CJ, Shea K, Carran S, et al. J R Soc Interface. 2018;15(140). doi: 10.1098/rsif.2017.0575.

Measles-Rubella supplementary immunization activity readiness assessment — India, 2017–2018.
Gurnani V, Haldar P, Khanal S, et al. MMWR Morb Mortal Wkly Rep. 2018;67(26):742–746. doi: 10.15585/mmwr.mm6726a3.

Progress toward measles elimination — Western Pacific Region, 2013–2017.
Hagan JE, Kriss JL, Takashima Y, et al. MMWR Morb Mortal Wkly Rep. 2018;67(17):491–495. doi: 10.15585/mmwr.mm6717a3.

A microneedle patch for measles and rubella vaccination is immunogenic and protective in infant rhesus macaques.
Joyce JC, Carroll TD, Collins ML, et al. J Infect Dis. 2018;218(1):124–132. doi: 10.1093/infdis/jiy139.

Healthcare-associated measles following a nationwide outbreak in Mongolia.
Lake JG, Luvsansharav UO, Hagan JE, et al. Clin Infect Dis. 2018;67(2):288–290. doi: 10.1093/cid/ciy067.

Global landscape of measles and rubella surveillance.
Patel MK, Gibson R, Cohen A, Dumolard L, Gacic-Dobo M. Vaccine. 2018;36(48):7385–7392. doi: 10.1016/j.vaccine.2018.10.007.

Use of the revised World Health Organization cluster survey methodology to classify measles-rubella vaccination campaign coverage in 47 counties in Kenya, 2016.
Subaiya S, Tabu C, N'ganga J, et al. PLoS One. 2018;13(7):e0199786. doi: 10.1371/journal.pone.0199786.